Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- CHEMM.CO
- Price
- 402.20
- Stock movement up
- +1.40 (0.35%)
- Company name
- ChemoMetec A/S
- Exchange
- (CO ,
- Currency
- DKK )
- Sector
- Healthcare >Medical Devices
- Market cap
- 7.00B
- Ent value
- 6.86B
- Price/Sales
- 7.35
- Price/Book
- 10.73
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- 119.15%
- Trailing P/E
- 20.22
- Forward P/E
- 22.89
- PEG
- -
- EPS growth
- 25.80%
- 1 year return (CAGR)
- -29.56%
- 3 year return (CAGR)
- -14.39%
- 5 year return (CAGR)
- -7.60%
- 10 year return (CAGR)
- 26.95%
Last updated: 2026-03-13
DIVIDENDS
CHEMM.CO does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 20.22 |
| Price to OCF | 18.12 |
| Price to FCF | 43.57 |
| Price to EBITDA | 39.78 |
| EV to EBITDA | 38.96 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 7.35 |
| Price to Book | 10.73 |
| EV to Sales | 7.20 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 17.40M |
| EPS (TTM) | 19.89 |
| FCF per share (TTM) | 9.23 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 952.66M |
| Gross profit (TTM) | 814.43M |
| Operating income (TTM) | 457.26M |
| Net income (TTM) | 346.11M |
| EPS (TTM) | 19.89 |
| EPS (1y forward) | 17.57 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 85.49% |
| Operating margin (TTM) | 48.00% |
| Profit margin (TTM) | 36.33% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 274.66M |
| Net receivables | 98.01M |
| Total current assets | 484.44M |
| Goodwill | 7.36M |
| Intangible assets | 160.55M |
| Property, plant and equipment | 216.16M |
| Total assets | 783.37M |
| Accounts payable | 13.68M |
| Short/Current long term debt | 8.07M |
| Total current liabilities | 123.28M |
| Total liabilities | 130.78M |
| Shareholder's equity | 652.59M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 386.28M |
| Capital expenditures (TTM) | 54.88M |
| Free cash flow (TTM) | 160.66M |
| Dividends paid (TTM) | 191.42M |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | 53.04% |
| Return on Assets | 44.18% |
| Return on Invested Capital | 52.85% |
| Cash Return on Invested Capital | 24.53% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 403.20 |
| Daily high | 411.00 |
| Daily low | 398.20 |
| Daily Volume | 50K |
| All-time high | 1128.00 |
| 1y analyst estimate | - |
| Beta | 1.59 |
| EPS (TTM) | 19.89 |
| Dividend per share | 0.00 |
| Ex-div date | 15 Oct 2021 |
| Next earnings date | 5 May 2026 |
Downside potential
Loading...
Downside potential data
| CHEMM.CO | S&P500 | |
| Current price drop from All-time high | -64.34% | -1.82% |
| Highest price drop | -88.30% | -56.47% |
| Date of highest drop | 28 Dec 2012 | 9 Mar 2009 |
| Avg drop from high | -45.44% | -10.84% |
| Avg time to new high | 42 days | 12 days |
| Max time to new high | 1941 days | 1805 days |
COMPANY DETAILS
Marketcap
7.00B
Marketcap category
Mid-cap
Description
ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in the areas of cell and gene therapy, cancer and stem cell research, and development and manufacturing of pharmaceuticals, as well as production and quality control of animal semen, milk, and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202, a consistent cell counter; NucleoCounter NC-200, an automated cell counter that provides solution for cell counting and cell viability determination; NucleoCounter SP-100, an automated sperm cell counter for use in animal reproduction; and XcytoMatic 40, a cell density and viability analyzer. In addition, the company provides consumables comprising cassettes, reagents, lysis, and slides; accessories, which include cables, power supplies, software, and labware products, as well as service and validation plans and training. Further, it develops XcytoMatic 30 cell counter and Xcyto 5, a versatile cell analyzer. ChemoMetec A/S was incorporated in 1997 and is headquartered in Allerød, Denmark.
Employees
172
Website
Investor relations
-
SEC filings
CEO
Country
Denmark
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
ANNOUNCEMENT NO. 302 2 March 2026 Notification of managers’ transactions ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions rela...
March 2, 2026
As European markets navigate through volatility, with the pan-European STOXX Europe 600 Index recently hitting a new high but ending broadly unchanged, investors are keenly observing how AI disruption...
February 19, 2026
ANNOUNCEMENT NO. 300 4 February 2026 ChemoMetec enters Letter of Intent with Roche Diagnostics ChemoMetec has entered a Letter of Intent with Roche Diagnostics aiming to pursue a collaboration with th...
February 4, 2026
ANNOUNCEMENT NO. 299 4 February 2026 Interim report for the first half of 2025/26 Organic growth despite challenges in the North American market Martin Helbo Behrens, CEO: In the first half of 2025/26...
February 4, 2026
ChemoMetec A/S recently reported first-quarter 2025 revenue exceeding forecasts alongside details of new product launches and a planned organizational restructuring. An important development is the co...
November 12, 2025
ChemoMetec (CPSE:CHEMM) has been on investors’ watchlists with a sharp upswing in its share price in the past 3 months. The stock is up over 50% during this period and has caught the attention of the ...
November 11, 2025
Trading statement for Q1 2025/26 (1 July - 30 September 2025) Growth in revenue and operating profit Revenue was up by 8% in Q1 2025/26 (11% at constant exchange rates) to DKK 124.6 million from DKK 1...
November 6, 2025
ANNOUNCEMENT NO. 295 28 October 2025 Upgrade of guidance ChemoMetec experiences an increased interest in its technology, not the least the XcytoMatic platform, and consequently expects a positive tren...
October 28, 2025
ANNOUNCEMENT NO. 294 9 October 2025 Procedure of the Annual General Meeting The Annual General Meeting of ChemoMetec A/S was held on 9 October 2025 at 5.30 p.m. at Nordsjællands KonferenceCenter. At t...
October 9, 2025
As the European markets navigate a complex landscape of interest rate policies and trade tensions, the pan-European STOXX Europe 600 Index has remained relatively stable, while major stock indexes in ...
October 2, 2025
Next page